CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it will host a virtual event on Wednesday, November 12, 2025, to discuss its liver disease franchise and strategy, with a focus on Wilson’s Disease. Prime Medicine remains on track to file an investigational new drug (IND) and/or clinical trial application (CTA) for PM577, its Prime Edi ...

Group 1 - Prime Medicine, Inc. closed its underwritten public offering of 43,700,000 shares of common stock at a price of $3.30 per share, raising approximately $144.2 million in gross proceeds before expenses [1] - The offering included the full exercise of the underwriters' option to purchase an additional 5,700,000 shares, with no discounts or commissions for 1,818,181 shares sold to the Cystic Fibrosis Foundation [1] - TD Cowen and BMO Capital Markets served as joint book-running managers for the offering [2] Group 2 - The shares were offered under an effective shelf registration statement filed with the SEC on November 3, 2023, and declared effective on November 13, 2023 [3] - A final prospectus supplement detailing the terms of the offering was filed with the SEC and is available on their website [3] Group 3 - Prime Medicine is focused on developing a new class of one-time curative genetic therapies using its proprietary Prime Editing platform, which aims for precise and efficient gene editing [6] - The company is advancing a diversified portfolio of investigational therapeutic programs in core areas such as liver, lung, immunology, and oncology, targeting diseases with well-understood biology [7]

Core Points - Prime Medicine, Inc. announced a public offering of 38,000,000 shares at a price of $3.30 per share, aiming to raise approximately $125.4 million in gross proceeds before expenses [1] - The offering includes a 30-day option for underwriters to purchase an additional 5,700,000 shares [1] - The offering is expected to close around August 1, 2025, pending customary closing conditions [1] Company Overview - Prime Medicine is a biotechnology company focused on developing one-time curative genetic therapies using its proprietary Prime Editing platform, which allows for precise gene editing [6] - The company is advancing a portfolio of investigational therapeutic programs in core areas such as liver, lung, immunology, and oncology, targeting diseases with well-understood biology [7] Offering Details - The shares are being offered under an effective shelf registration statement filed with the SEC on November 3, 2023, and declared effective on November 13, 2023 [3] - The final prospectus supplement will be filed with the SEC and will be available through designated contacts [4]

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of its common stock offered in the public offering. All of the shares ...